SG11202100767XA - Methods for treating neurodegenerative disorders - Google Patents

Methods for treating neurodegenerative disorders

Info

Publication number
SG11202100767XA
SG11202100767XA SG11202100767XA SG11202100767XA SG11202100767XA SG 11202100767X A SG11202100767X A SG 11202100767XA SG 11202100767X A SG11202100767X A SG 11202100767XA SG 11202100767X A SG11202100767X A SG 11202100767XA SG 11202100767X A SG11202100767X A SG 11202100767XA
Authority
SG
Singapore
Prior art keywords
methods
neurodegenerative disorders
treating neurodegenerative
treating
disorders
Prior art date
Application number
SG11202100767XA
Other languages
English (en)
Inventor
John Hey
Petr Kocis
Martin Tolar
Neil William Flanzraich
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of SG11202100767XA publication Critical patent/SG11202100767XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
SG11202100767XA 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders SG11202100767XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01
PCT/US2019/044023 WO2020028290A1 (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
SG11202100767XA true SG11202100767XA (en) 2021-02-25

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100767XA SG11202100767XA (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders

Country Status (27)

Country Link
US (2) US12083082B2 (https=)
EP (1) EP3829563B1 (https=)
JP (1) JP7573512B2 (https=)
KR (1) KR102716959B1 (https=)
CN (1) CN112867485A (https=)
AU (1) AU2019315853B2 (https=)
BR (1) BR112021001739A2 (https=)
CL (1) CL2021000269A1 (https=)
DK (1) DK3829563T3 (https=)
EA (1) EA202190406A1 (https=)
ES (1) ES3011716T3 (https=)
FI (1) FI3829563T3 (https=)
HR (1) HRP20250206T1 (https=)
HU (1) HUE070101T2 (https=)
IL (1) IL280424B2 (https=)
LT (1) LT3829563T (https=)
MX (1) MX2021001287A (https=)
MY (1) MY206530A (https=)
PH (1) PH12021550213A1 (https=)
PL (1) PL3829563T3 (https=)
PT (1) PT3829563T (https=)
RS (1) RS66516B1 (https=)
SG (1) SG11202100767XA (https=)
SI (1) SI3829563T1 (https=)
SM (1) SMT202500080T1 (https=)
UA (1) UA130011C2 (https=)
WO (1) WO2020028290A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025504A2 (pt) * 2019-06-17 2022-04-26 Alzheon Inc Métodos para tratar distúrbios neurodegenerativos
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
WO2014121083A1 (en) 2013-01-31 2014-08-07 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
CA2941415A1 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
FI3347002T3 (fi) 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa

Also Published As

Publication number Publication date
PH12021550213A1 (en) 2021-11-03
CA3108150A1 (en) 2020-02-06
US12083082B2 (en) 2024-09-10
KR102716959B1 (ko) 2024-10-11
CN112867485A (zh) 2021-05-28
FI3829563T3 (fi) 2025-02-17
AU2019315853B2 (en) 2025-05-01
EA202190406A1 (ru) 2021-10-15
MX2021001287A (es) 2021-07-15
JP2021533128A (ja) 2021-12-02
PT3829563T (pt) 2025-02-18
US20210315847A1 (en) 2021-10-14
HUE070101T2 (hu) 2025-05-28
IL280424A (en) 2021-03-01
US20250213507A1 (en) 2025-07-03
KR20210039415A (ko) 2021-04-09
MY206530A (en) 2024-12-19
CL2021000269A1 (es) 2021-06-18
SI3829563T1 (sl) 2025-05-30
ES3011716T3 (en) 2025-04-08
EP3829563B1 (en) 2024-11-20
UA130011C2 (uk) 2025-10-15
BR112021001739A2 (pt) 2021-04-27
IL280424B1 (en) 2024-09-01
RS66516B1 (sr) 2025-03-31
IL280424B2 (en) 2025-01-01
HRP20250206T1 (hr) 2025-04-11
PL3829563T3 (pl) 2025-04-07
AU2019315853A1 (en) 2021-03-18
WO2020028290A1 (en) 2020-02-06
DK3829563T3 (en) 2025-02-24
LT3829563T (lt) 2025-02-25
EP3829563A1 (en) 2021-06-09
JP7573512B2 (ja) 2024-10-25
SMT202500080T1 (it) 2025-03-12

Similar Documents

Publication Publication Date Title
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
IL267082A (en) Systems and methods for the treatment of neurological disorders
IL262222A (en) Anti-aging antibodies for the treatment of neurodegenerative disorders
IL273705A (en) Benzothiazole compounds and methods of using them for the treatment of neurodegenerative diseases
IL281052A (en) Treatment of liver disorders
PT3119911T (pt) Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+
SG10201913400QA (en) Methods for treating lung disorders
ZA201800831B (en) Compositions and methods for treating and preventing neurodegenerative disorders
GB201803010D0 (en) Neurodegenerative disorders
SG11202007286TA (en) Methods for treating mitochondrial disorders
EP3313387A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
DK4296670T3 (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
IL280424A (en) Methods for treating neurodegenerative disorders
IL286571A (en) Compounds and methods for the treatment of neurodegenerative disorders
GB201701404D0 (en) Therapies for treating inflammatory disorders
IL289018A (en) Methods for treating neurodegenerative disorders
HK40072836A (en) Methods for treating neurodegenerative disorders
HK40019969A (en) Methods for treating neurodegenerative disorders
HK40069546A (en) Methods for treating neurodegenerative disorders
HK40017730A (en) Methods for treating mitochondrial disorders
PT3420084T (pt) Nova abordagem para tratamento de disfunções inflamatórias